Market Research Logo

Neuroendocrine Carcinoma Market: Targeted Therapy Projected to be the Fastest Growing Segment by Treatment Type Through 2027: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)

Neuroendocrine Carcinoma Market: Targeted Therapy Projected to be the Fastest Growing Segment by Treatment Type Through 2027: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)

Future Market Insights has revealed various facts on the neuroendocrine carcinoma market in its recently published research report titled “Neuroendocrine Carcinoma Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)”. This research study is filled with incisive market insights and essential acumen and reflects various factors that have contributed to the growth of the global market. Along with the past market scenario, a glimpse of the future of the neuroendocrine carcinoma market is also portrayed. The forecast analysis is for five years, from 2017 to 2022. This can assist the reader in slating important strategies based on present market conditions to achieve expansion in the coming future.

A 3600 view of the entire market

Research study on neuroendocrine carcinoma market puts forth a global 3600 perspective. Main geographies across the entire globe are assessed and the trends, developments, opportunities, drivers and challenges in each region and sub region that have an influence over the growth of the market in the respective region are studied to get a clear picture of the global endocrine carcinoma market. Revenue pockets can be derived with such kind of intense market intelligence which is unbiased in nature and purely market centric thus portraying a global perspective in front of the reader.

Unparalleled research methodology for a unique research study

Future Market Insights follows a one of a kind research methodology to glean vital and relevant market insights. This research process ensures delivery of statistical data without errors, thus maximizing the accuracy of the research report. Secondary research in combination with primary research gives a clear market understanding based on which key players, market observers and opinion leaders are interviewed to check the reliability of the data and to add other facets of the market. The uniqueness of this research process is the revalidation and re-evaluation of the data that takes place at each step during each interview and is continued till the conclusion of the market research. Based on these vital acumen, key analysis can be drawn and recommendations from domain experts are included in this intelligence report. The multiple cross checking of the data ensures a highly accurate market scenario which can be directly used by the reader to chalk informed decisions.

The research report on global neuroendocrine carcinoma market covers analysis on key companies dealing with neuroendocrine carcinoma. Various aspects such as SWOT analysis, key developments, innovations, product portfolio, financials and company overview are included in this section of the report. The reader can gain intelligence on the major players that have a good hold in the market, based on which new strategies can be devised to gain an edge on the competition. The weighted market analysis on global neuroendocrine carcinoma market delivers value to the reader by providing drinkable insights, ready to use statistical analysis and recommendations without biasness in order to plan future expansion strategies and also to gain stability in the changing dynamics of the global market.


1. Executive Summary
A gist of the report, highlighting the key takeaways
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
A definition of Neuroendocrine Carcinoma market taxonomy
2.1. Market Taxonomy
2.2. Market Definition
2.3. Market Overview
3. Neuroendocrine Carcinoma Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Neuroendocrine Carcinoma Pipeline Snapshot
3.4. Neuroendocrine Carcinoma Reimbursement Scenario
3.5. Neuroendocrine Carcinoma Regulations
3.6. Neuroendocrine Carcinoma Epidemiology
4. North America Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
4.5.1. Gastric Neuroendocrine Tumors
4.5.2. Lung Neuroendocrine Tumors
4.5.3. Pancreatic Neuroendocrine Tumors
4.5.4. Appendiceal Neuroendocrine Tumors
4.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
4.6.1. Gastric Neuroendocrine Tumors
4.6.2. Lung Neuroendocrine Tumors
4.6.3. Pancreatic Neuroendocrine Tumors
4.6.4. Appendiceal Neuroendocrine Tumors
4.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
4.7.1. Chemotherapy
4.7.2. Antimetabolites
4.7.3. Alkylating agents
4.7.4. Natural Products
4.7.5. Targeted Therapy
4.7.6. Tyrosine Kinase Inhibitor
4.7.7. mTOR Inhibitor
4.7.8. Somatostatin Analogs
4.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
4.8.1. Chemotherapy
4.8.2. Antimetabolites
4.8.3. Alkylating agents
4.8.4. Natural Products
4.8.5. Targeted Therapy
4.8.6. Tyrosine Kinase Inhibitor
4.8.7. mTOR Inhibitor
4.8.8. Somatostatin Analogs
4.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
4.9.1. Hospitals
4.9.2. Clinics
4.9.3. Oncology Centers
4.9.4. Ambulatory Surgery Centers
4.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
4.10.1. Hospitals
4.10.2. Clinics
4.10.3. Oncology Centers
4.10.4. Ambulatory Surgery Centers
4.11. Market Attractiveness Analysis
4.11.1. By Country
4.11.2. By Disease Indication Type
4.11.3. By Treatment Type
4.11.4. By End User
4.12. Key Representative Market Participants
4.13. Key Participants Market Presence (Intensity Map)
5. Western Europe Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) By Country, 2012-2016
5.3.1. Germany
5.3.2. United Kingdom
5.3.3. France
5.3.4. Italy
5.3.5. Spain
5.3.6. Rest of Western Europe
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Germany
5.4.2. United Kingdom
5.4.3. France
5.4.4. Italy
5.4.5. Spain
5.4.6. Rest of Western Europe
5.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
5.5.1. Gastric Neuroendocrine Tumors
5.5.2. Lung Neuroendocrine Tumors
5.5.3. Pancreatic Neuroendocrine Tumors
5.5.4. Appendiceal Neuroendocrine Tumors
5.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
5.6.1. Gastric Neuroendocrine Tumors
5.6.2. Lung Neuroendocrine Tumors
5.6.3. Pancreatic Neuroendocrine Tumors
5.6.4. Appendiceal Neuroendocrine Tumors
5.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
5.7.1. Chemotherapy
5.7.2. Antimetabolites
5.7.3. Alkylating agents
5.7.4. Natural Products
5.7.5. Targeted Therapy
5.7.6. Tyrosine Kinase Inhibitor
5.7.7. mTOR Inhibitor
5.7.8. Somatostatin Analogs
5.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
5.8.1. Chemotherapy
5.8.2. Antimetabolites
5.8.3. Alkylating agents
5.8.4. Natural Products
5.8.5. Targeted Therapy
5.8.6. Tyrosine Kinase Inhibitor
5.8.7. mTOR Inhibitor
5.8.8. Somatostatin Analogs
5.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
5.9.1. Hospitals
5.9.2. Clinics
5.9.3. Oncology Centers
5.9.4. Ambulatory Surgery Centers
5.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
5.10.1. Hospitals
5.10.2. Clinics
5.10.3. Oncology Centers
5.10.4. Ambulatory Surgery Centers
5.11. Market Attractiveness Analysis
5.11.1. By Country
5.11.2. By Disease Indication Type
5.11.3. By Treatment Type
5.11.4. By End User
5.12. Key Representative Market Participants
5.13. Key Participants Market Presence (Intensity Map)
6. Eastern Europe Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) By Country, 2012-2016
6.3.1. Russia
6.3.2. Poland
6.3.3. Rest of Eastern Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. Russia
6.4.2. Poland
6.4.3. Rest of Eastern Europe
6.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
6.5.1. Gastric Neuroendocrine Tumors
6.5.2. Lung Neuroendocrine Tumors
6.5.3. Pancreatic Neuroendocrine Tumors
6.5.4. Appendiceal Neuroendocrine Tumors
6.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
6.6.1. Gastric Neuroendocrine Tumors
6.6.2. Lung Neuroendocrine Tumors
6.6.3. Pancreatic Neuroendocrine Tumors
6.6.4. Appendiceal Neuroendocrine Tumors
6.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
6.7.1. Chemotherapy
6.7.2. Antimetabolites
6.7.3. Alkylating agents
6.7.4. Natural Products
6.7.5. Targeted Therapy
6.7.6. Tyrosine Kinase Inhibitor
6.7.7. mTOR Inhibitor
6.7.8. Somatostatin Analogs
6.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
6.8.1. Chemotherapy
6.8.2. Antimetabolites
6.8.3. Alkylating agents
6.8.4. Natural Products
6.8.5. Targeted Therapy
6.8.6. Tyrosine Kinase Inhibitor
6.8.7. mTOR Inhibitor
6.8.8. Somatostatin Analogs
6.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
6.9.1. Hospitals
6.9.2. Clinics
6.9.3. Oncology Centers
6.9.4. Ambulatory Surgery Centers
6.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
6.10.1. Hospitals
6.10.2. Clinics
6.10.3. Oncology Centers
6.10.4. Ambulatory Surgery Centers
6.11. Market Attractiveness Analysis
6.11.1. By Country
6.11.2. By Disease Indication Type
6.11.3. By Treatment Type
6.11.4. By End User
6.12. Key Representative Market Participants
6.13. Key Participants Market Presence (Intensity Map)
7. Latin America Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Trends
7.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
7.3.1. Brazil
7.3.2. Mexico
7.3.3. Rest of Latin America
7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
7.5.1. Gastric Neuroendocrine Tumors
7.5.2. Lung Neuroendocrine Tumors
7.5.3. Pancreatic Neuroendocrine Tumors
7.5.4. Appendiceal Neuroendocrine Tumors
7.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
7.6.1. Gastric Neuroendocrine Tumors
7.6.2. Lung Neuroendocrine Tumors
7.6.3. Pancreatic Neuroendocrine Tumors
7.6.4. Appendiceal Neuroendocrine Tumors
7.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
7.7.1. Chemotherapy
7.7.2. Antimetabolites
7.7.3. Alkylating agents
7.7.4. Natural Products
7.7.5. Targeted Therapy
7.7.6. Tyrosine Kinase Inhibitor
7.7.7. mTOR Inhibitor
7.7.8. Somatostatin Analogs
7.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
7.8.1. Chemotherapy
7.8.2. Antimetabolites
7.8.3. Alkylating agents
7.8.4. Natural Products
7.8.5. Targeted Therapy
7.8.6. Tyrosine Kinase Inhibitor
7.8.7. mTOR Inhibitor
7.8.8. Somatostatin Analogs
7.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
7.9.1. Hospitals
7.9.2. Clinics
7.9.3. Oncology Centers
7.9.4. Ambulatory Surgery Centers
7.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
7.10.1. Hospitals
7.10.2. Clinics
7.10.3. Oncology Centers
7.10.4. Ambulatory Surgery Centers
7.11. Market Attractiveness Analysis
7.11.1. By Country
7.11.2. By Disease Indication Type
7.11.3. By Treatment Type
7.11.4. By End User
7.12. Key Representative Market Participants
7.13. Key Participants Market Presence (Intensity Map)
8. Asia Pacific Excluding Japan Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) By Country, 2012-2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
8.5.1. Gastric Neuroendocrine Tumors
8.5.2. Lung Neuroendocrine Tumors
8.5.3. Pancreatic Neuroendocrine Tumors
8.5.4. Appendiceal Neuroendocrine Tumors
8.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
8.6.1. Gastric Neuroendocrine Tumors
8.6.2. Lung Neuroendocrine Tumors
8.6.3. Pancreatic Neuroendocrine Tumors
8.6.4. Appendiceal Neuroendocrine Tumors
8.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
8.7.1. Chemotherapy
8.7.2. Antimetabolites
8.7.3. Alkylating agents
8.7.4. Natural Products
8.7.5. Targeted Therapy
8.7.6. Tyrosine Kinase Inhibitor
8.7.7. mTOR Inhibitor
8.7.8. Somatostatin Analogs
8.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
8.8.1. Chemotherapy
8.8.2. Antimetabolites
8.8.3. Alkylating agents
8.8.4. Natural Products
8.8.5. Targeted Therapy
8.8.6. Tyrosine Kinase Inhibitor
8.8.7. mTOR Inhibitor
8.8.8. Somatostatin Analogs
8.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
8.9.1. Hospitals
8.9.2. Clinics
8.9.3. Oncology Centers
8.9.4. Ambulatory Surgery Centers
8.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
8.10.1. Hospitals
8.10.2. Clinics
8.10.3. Oncology Centers
8.10.4. Ambulatory Surgery Centers
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Disease Indication Type
8.11.3. By Treatment Type
8.11.4. By End User
8.12. Key Representative Market Participants
8.13. Key Participants Market Presence (Intensity Map)
9. Japan Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
9.1. Introduction
9.2. Regional Market Dynamics
9.2.1. Drivers
9.2.2. Restraints
9.2.3. Trends
9.3. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
9.3.1. Gastric Neuroendocrine Tumors
9.3.2. Lung Neuroendocrine Tumors
9.3.3. Pancreatic Neuroendocrine Tumors
9.3.4. Appendiceal Neuroendocrine Tumors
9.4. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
9.4.1. Gastric Neuroendocrine Tumors
9.4.2. Lung Neuroendocrine Tumors
9.4.3. Pancreatic Neuroendocrine Tumors
9.4.4. Appendiceal Neuroendocrine Tumors
9.5. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
9.5.1. Chemotherapy
9.5.2. Antimetabolites
9.5.3. Alkylating agents
9.5.4. Natural Products
9.5.5. Targeted Therapy
9.5.6. Tyrosine Kinase Inhibitor
9.5.7. mTOR Inhibitor
9.5.8. Somatostatin Analogs
9.6. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
9.6.1. Chemotherapy
9.6.2. Antimetabolites
9.6.3. Alkylating agents
9.6.4. Natural Products
9.6.5. Targeted Therapy
9.6.6. Tyrosine Kinase Inhibitor
9.6.7. mTOR Inhibitor
9.6.8. Somatostatin Analogs
9.7. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
9.7.1. Hospitals
9.7.2. Clinics
9.7.3. Oncology Centers
9.7.4. Ambulatory Surgery Centers
9.8. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
9.8.1. Hospitals
9.8.2. Clinics
9.8.3. Oncology Centers
9.8.4. Ambulatory Surgery Centers
9.9. Market Attractiveness Analysis
9.9.1. By Country
9.9.2. By Disease Indication Type
9.9.3. By Treatment Type
9.9.4. By End User
9.10. Key Representative Market Participants
9.11. Key Participants Market Presence (Intensity Map)
10. Middle East and Africa Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
Analysis highlighting historical trends, current market value, and future projections on the basis of key segments
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of MEA
10.4. Market Size (US$ Mn) and Forecast By Country, , 2017–2027
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of MEA
10.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
10.5.1. Gastric Neuroendocrine Tumors
10.5.2. Lung Neuroendocrine Tumors
10.5.3. Pancreatic Neuroendocrine Tumors
10.5.4. Appendiceal Neuroendocrine Tumors
10.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
10.6.1. Gastric Neuroendocrine Tumors
10.6.2. Lung Neuroendocrine Tumors
10.6.3. Pancreatic Neuroendocrine Tumors
10.6.4. Appendiceal Neuroendocrine Tumors
10.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
10.7.1. Chemotherapy
10.7.2. Antimetabolites
10.7.3. Alkylating agents
10.7.4. Natural Products
10.7.5. Targeted Therapy
10.7.6. Tyrosine Kinase Inhibitor
10.7.7. mTOR Inhibitor
10.7.8. Somatostatin Analogs
10.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
10.8.1. Chemotherapy
10.8.2. Antimetabolites
10.8.3. Alkylating agents
10.8.4. Natural Products
10.8.5. Targeted Therapy
10.8.6. Tyrosine Kinase Inhibitor
10.8.7. mTOR Inhibitor
10.8.8. Somatostatin Analogs
10.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
10.9.1. Hospitals
10.9.2. Clinics
10.9.3. Oncology Centers
10.9.4. Ambulatory Surgery Centers
10.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
10.10.1. Hospitals
10.10.2. Clinics
10.10.3. Oncology Centers
10.10.4. Ambulatory Surgery Centers
10.11. Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Disease Indication Type
10.11.3. By Treatment Type
10.11.4. By End User
10.12. Key Representative Market Participants
10.13. Key Participants Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
Profile of some of the key market players, with specific focus on business and product strategy
13.1. Market Structure
13.2. Competition Dashboard
13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
13.3.1. Pfizer Inc.
13.3.2. Novartis AG
13.3.3. Chiasma Inc.
13.3.4. Ipsen
13.3.5. Abbvie Inc.
13.3.6. Valeant Pharmaceuticals International Inc.
13.3.7. Jubilant Life Sciences Ltd.
13.3.8. Teva Pharmaceutical Industries Ltd
13.3.9. F.Hoffmann-La Roche Ltd
13.3.10. Advanced Accelerator Applications
13.3.11. Mateon Therapeutics, Inc.
13.3.12. Lexicon Pharmaceuticals, Inc.
13.3.13. Isotopen Technologien München AGGlobal
13.3.14. Hutchison China MediTech Ltd
13.3.15. Amgen Inc
13.3.16. Celgene Corporation
13.3.17. Mallinckrodt plc.
13.3.18. Dauntless Pharmaceuticals, Inc.
14. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) By Region
14.2.1. North America
14.2.2. Western Europe
14.2.3. Eastern Europe
14.2.4. Latin America
14.2.5. Asia Pacific Excluding Japan
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region
14.3.1. North America
14.3.2. Western Europe
14.3.3. Eastern Europe
14.3.4. Latin America
14.3.5. Asia Pacific Excluding Japan
14.3.6. Japan
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016
15.2.1. Gastric Neuroendocrine Tumors
15.2.2. Lung Neuroendocrine Tumors
15.2.3. Pancreatic Neuroendocrine Tumors
15.2.4. Appendiceal Neuroendocrine Tumors
15.3. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027
15.3.1. Gastric Neuroendocrine Tumors
15.3.2. Lung Neuroendocrine Tumors
15.3.3. Pancreatic Neuroendocrine Tumors
15.3.4. Appendiceal Neuroendocrine Tumors
15.4. Market Attractiveness Analysis By Disease Indication Type
16. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016
16.2.1. Chemotherapy
16.2.2. Antimetabolites
16.2.3. Alkylating agents
16.2.4. Natural Products
16.2.5. Targeted Therapy
16.2.6. Tyrosine Kinase Inhibitor
16.2.7. mTOR Inhibitor
16.2.8. Somatostatin Analogs
16.3. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027
16.3.1. Chemotherapy
16.3.2. Antimetabolites
16.3.3. Alkylating agents
16.3.4. Natural Products
16.3.5. Targeted Therapy
16.3.6. Tyrosine Kinase Inhibitor
16.3.7. mTOR Inhibitor
16.3.8. Somatostatin Analogs
16.4. Market Attractive Analysis By End User
17. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By End User
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016
17.2.1. Hospitals
17.2.2. Clinics
17.2.3. Oncology Centers
17.2.4. Ambulatory Surgery Centers
17.3. Market Size (US$ Mn) and Forecast, By End User , 2017–2027
17.3.1. Hospitals
17.3.2. Clinics
17.3.3. Oncology Centers
17.3.4. Ambulatory Surgery Centers
17.4. Market Attractive Analysis By End User
18. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027
18.1. Market Size and Y-o-Y Growth
18.2. Absolute $ Opportunity
19. Assumptions and Acronyms Used
A glossary of assumption and acronyms used in the report
20. Research Methodology
List of Tables
Table 01: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 02: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 03: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 04: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 05: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 06: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 07: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 08: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 09: Eastern Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 10: Eastern Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 11: Eastern Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 12: Eastern Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 13: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 14: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 15: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 16: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 17: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 18: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 19: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 20: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 21: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 22: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 23: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 24: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 25: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 26: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 27: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 28: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 29: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type
Table 30: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type
Table 31: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report